多种肿瘤标志物联合检测在胃肠道肿瘤临床诊断中的价值  

Diagnostic Value of Multiple Tumor Markers Combined Detection in the Gastrointestinal Tumors

作　　者：王留伟[1] 李丰[1] 赵林海[1] WANG Liuwei;LI Feng;ZHAO Linhai(Zhoukou Central Hospital, Zhoukou 466000, China)

机构地区：[1]周口市中心医院,河南周口466000

出　　处：《肿瘤基础与临床》2018年第5期395-397,共3页journal of basic and clinical oncology

摘　　要：目的探讨多种肿瘤标志物联合检测在胃肠道肿瘤临床疗效评估及其转移复发判断中的价值。方法入组的30例胃肠道肿瘤患者分为6个等级,并收集30例非胃肠道肿瘤患者数据作为对照,运用统计学方法分析各肿瘤标志物表达水平与病情分级的关系及与临床疗效的相关性,并运用肿瘤复发转移的判别方程判断疾病进展。结果胃肠道肿瘤患者血清中癌胚抗原、甲胎蛋白、癌抗原19-9、癌抗原72-4、癌抗原242的表达水平均显著高于健康对照组(P均<0.05);与临床疗效均具有相关性(P<0.05);根据转移判别方程,胃肠道肿瘤患者中各肿瘤标志物的诊断结果与健康对照组差异均有统计学意义(P<0.05)。结论多种肿瘤标志物联合检测与胃肠道肿瘤临床疗效的具有相关性,其在判断胃肠道肿瘤转移复发中的具有诊断价值。Objective To investigate the diagnostic value of multiple tumor markers combined detection in the gastrointestinal tumors.Methods Thirty patients with gastrointestinal tumors were divided into six grades,and30patients with non gastrointestinal tumors were collected,statistical methods were used to analyze the expression level of tumor markers and the relationship and correlation with clinical curative effect of disease classification,and the discriminant equation of recurrence and metastasis of tumors was used to determine the disease progression.Results The serum expression levels of carcinoembryonic antigen,alpha fetoprotein,cancer antigen19-9,cancer antigen72-4and cancer antigen242of patients with gastrointestinal tumors were significantly higher than that of the healthy controls(P<0.05);the correlation of clinical curative effect analysis were statistically significant(P<0.05);according to the discriminant equation,the transfer of all the tumor markers in patients with gastrointestinal tumors diagnosis had the significant difference for the healthy control group(P<0.05).Conclusion Multiple tumor markers combined detection has the correlation with clinical curative effect of gastrointestinal tumors,and has the diagnostic value in the recurrence and metastasis gastrointestinal tumors.

关 键 词：胃肠道肿瘤 癌胚抗原 甲胎蛋白 癌抗原19-9 癌抗原72-4 癌抗原242 

分 类 号：R735[医药卫生—肿瘤] R730.4[医药卫生—临床医学]